ARTICLE | Product Development
Pharmas challenging Novo and Lilly in obesity
An analysis of which major pharmas are in, out, or still deciding whether to take on obesity heavyweights Eli Lilly and Novo Nordisk
November 15, 2024 10:20 PM UTC
Eli Lilly and Novo Nordisk have clearly set themselves apart from other pharmas in the scale of their pipelines, revenues and business development activities in obesity. But with what is projected to be the largest-ever market opportunity, other pharmas aren’t sitting this one out. Or are they?
A BioCentury analysis of obesity programs and deals reveals a broad spectrum of activity among major pharma companies, with some making a real push to compete with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO), while others are either dipping their toes in or steering clear of the water altogether, at least for now. ...